Ro Launches Wegovy Pill Through Integration with Novo Nordisk Ro to play critical role in ensuring patients nationwide get access to first and only oral GLP-1 weight loss medication at the lowest available cash price January 5, 2026 -- Ro, the leading direct-to-patient healthcare company, announced today that it is working with Novo Nordisk on the nationwide launch of the new Wegovy pill
Retatrutide, a triple hormone receptor agonist for obesity: A randomized, phase 2 trial
Retatrutide may cause mild side effects such as nausea, vomiting, diarrhea, constipation, or stomach discomfort, which often improve as your body adjusts
Because these medications can decrease appetite, prioritizing nutrient-rich foods and vegetables, along with plenty of protein and fiber, can help ensure you're getting all the important nutrients your body needs